Literature DB >> 3878487

Amphotericin clearance in vitrectomized versus nonvitrectomized eyes.

B H Doft, J Weiskopf, I Nilsson-Ehle, L B Wingard.   

Abstract

Ocular clearance of amphotericin B after direct intravitreal injection was studied in a rabbit model. Unmodified phakic eyes, Candida-infected eyes, aphakic eyes, and aphakic vitrectomized eyes were employed. Using high pressure liquid chromatography to assess drug level, the half-lives of drug disappearance after single 10-microgram (microgram) intravitreal injections were 9.1, 8.6, 4.7, and 1.4 days, respectively. The disappearance slope for vitrectomized eyes was significantly different from all nonvitrectomized eyes with P less than 0.001. The rapid disappearance of amphotericin from vitrectomized eyes must be considered in clinical management of patients with fungal endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878487     DOI: 10.1016/s0161-6420(85)33838-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  [Rational antibiotic therapy in ophthalmology].

Authors:  W Behrens-Baumann; U Frank; T Ness
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

Review 2.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

3.  RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Susan B Bressler; Michele Melia; Adam R Glassman; Talat Almukhtar; Lee M Jampol; Michel Shami; Brian B Berger; Neil M Bressler
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

4.  Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Ryo Terao; Kentaro Yuda; Kayo Kure; Tatsuya Inoue; Hiroshi Ohtsu; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-01-10       Impact factor: 2.447

Review 5.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

6.  Candida endophthalmitis.

Authors:  H M Towler; S Lightman; M Matheson
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

7.  Congenital stationary nightblindness in a patient with osteopetrosis.

Authors:  Y Matsui; S Okinami; S Oono; M Matsui
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

Review 8.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

9.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 10.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.